Compare Stocks

Date Range: 

 AllakosBlueprint MedicinesIonis PharmaceuticalsGalapagosTG Therapeutics
SymbolNASDAQ:ALLKNASDAQ:BPMCNASDAQ:IONSNASDAQ:GLPGNASDAQ:TGTX
Price Information
Current Price$91.24$83.69$37.78$69.22$37.91
52 Week RangeBuyBuyHoldHoldBuy
MarketRank™
Overall Score1.52.21.61.51.8
Analysis Score3.54.33.24.13.4
Community Score2.32.92.32.63.3
Dividend Score0.00.00.00.00.0
Ownership Score1.71.71.70.01.7
Earnings & Valuation Score0.01.90.60.60.6
Analyst Ratings
Consensus RecommendationBuyBuyHoldHoldBuy
Consensus Price Target$197.67$114.93$58.05$129.20$64.00
% Upside from Price Target116.64% upside37.33% upside53.64% upside86.65% upside68.82% upside
Trade Information
Market Cap$4.89 billion$4.88 billion$5.33 billion$4.54 billion$5.36 billion
Beta0.920.691.090.572.16
Average Volume249,390468,4021,469,681285,4361,445,985
Sales & Book Value
Annual RevenueN/A$793.73 million$729 million$605.66 million$150,000.00
Price / SalesN/A6.157.317.4935,753.68
CashflowN/A$5.55 per shareN/AN/AN/A
Price / CashN/A15.09N/AN/AN/A
Book Value$12.46 per share$26.38 per share$6.03 per share$46.63 per share$3.95 per share
Price / BookN/A3.176.271.489.60
Profitability
Net Income$-153,480,000.00$313.88 million$-451,290,000.00$-348,900,000.00$-279,380,000.00
EPS($3.10)$5.59($3.23)($5.36)($2.42)
Trailing P/E RatioN/A14.87N/AN/AN/A
Forward P/E RatioN/AN/AN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net MarginsN/A40.18%-69.63%-45.08%-35,158.99%
Return on Equity (ROE)-34.01%27.25%-41.74%-10.05%-95.94%
Return on Assets (ROA)-31.27%22.74%-18.24%-4.76%-73.19%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/AN/A1.28%N/AN/A
Current Ratio27.48%8.34%6.74%8.77%5.78%
Quick Ratio27.48%8.20%6.67%8.77%5.78%
Ownership Information
Institutional Ownership Percentage72.92%99.11%86.17%10.05%69.11%
Insider Ownership Percentage34.45%3.34%2.96%2.91%10.20%
Miscellaneous
Employees1414517571,304301
Shares Outstanding53.57 million58.34 million140.96 million65.52 million141.47 million
Next Earnings Date8/9/2021 (Estimated)7/29/2021 (Estimated)8/4/2021 (Estimated)8/5/2021 (Estimated)8/9/2021 (Estimated)
OptionableNot OptionableOptionableOptionableOptionableOptionable
SourceHeadline
Looking Into TG Therapeuticss Return On Capital EmployedLooking Into TG Therapeutics's Return On Capital Employed
benzinga.com - June 23 at 11:30 AM
Interesting TGTX Put And Call Options For February 2022Interesting TGTX Put And Call Options For February 2022
nasdaq.com - June 21 at 2:58 PM
TG Therapeutics, Inc. (NASDAQ:TGTX) Expected to Announce Earnings of -$0.48 Per ShareTG Therapeutics, Inc. (NASDAQ:TGTX) Expected to Announce Earnings of -$0.48 Per Share
americanbankingnews.com - June 20 at 9:10 PM
With 52.96% Distance From Low, Is TG Therapeutics Inc. (NASDAQ:TGTX) Poised For More Gains?With 52.96% Distance From Low, Is TG Therapeutics Inc. (NASDAQ:TGTX) Poised For More Gains?
marketingsentinel.com - June 19 at 11:38 AM
TG Therapeutics Announces Presentation of Data from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis at 7th Congress of the European Academy of NeurologyTG Therapeutics Announces Presentation of Data from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis at 7th Congress of the European Academy of Neurology
finance.yahoo.com - June 18 at 5:38 PM
TG Therapeutics Announces Preclinical and Clinical Data Evaluating TG-1701 at the 16th International Congress on Malignant LymphomaTG Therapeutics Announces Preclinical and Clinical Data Evaluating TG-1701 at the 16th International Congress on Malignant Lymphoma
finance.yahoo.com - June 18 at 12:38 PM
TG Therapeutics Inc. (NASDAQ: TGTX) Inclined 3.96% Over The Last Month – Are There Ways To Succeed From This Incline?TG Therapeutics Inc. (NASDAQ: TGTX) Inclined 3.96% Over The Last Month – Are There Ways To Succeed From This Incline?
marketingsentinel.com - June 12 at 5:05 PM
TG Therapeutics Announces Data from a Phase 1 Study Evaluating TG-1701 as a Monotherapy and as a Triple Combination with Ublituximab and UKONIQ® at the 2021 European Hematology Association Virtual CongressTG Therapeutics Announces Data from a Phase 1 Study Evaluating TG-1701 as a Monotherapy and as a Triple Combination with Ublituximab and UKONIQ® at the 2021 European Hematology Association Virtual Congress
finance.yahoo.com - June 11 at 7:44 AM
TG Therapeutics Announces Data Presentations at the Upcoming 16th International Congress on Malignant LymphomaTG Therapeutics Announces Data Presentations at the Upcoming 16th International Congress on Malignant Lymphoma
finance.yahoo.com - June 9 at 7:24 AM
Return On Capital Employed Overview: TG TherapeuticsReturn On Capital Employed Overview: TG Therapeutics
benzinga.com - June 7 at 12:36 PM
TG Therapeutics Announces Data from a Phase 1 Study Evaluating TG-1701 as a Monotherapy and as a Triple Combination with Ublituximab and UKONIQ® at the 2021 American Society of Clinical Oncology Annual MeetingTG Therapeutics Announces Data from a Phase 1 Study Evaluating TG-1701 as a Monotherapy and as a Triple Combination with Ublituximab and UKONIQ® at the 2021 American Society of Clinical Oncology Annual Meeting
finance.yahoo.com - June 4 at 10:06 AM
TG Therapeutics Inc. (NASDAQ: TGTX) Continues To DeclineTG Therapeutics Inc. (NASDAQ: TGTX) Continues To Decline
stocksregister.com - June 2 at 2:48 PM
TG Therapeutics, Inc. (NASDAQ:TGTX)’s Share Price Fell Recently, Although No Trouble Is On The HorizonTG Therapeutics, Inc. (NASDAQ:TGTX)’s Share Price Fell Recently, Although No Trouble Is On The Horizon
stocksregister.com - May 25 at 11:30 PM
H.C. Wainwright Stick to Their Buy Rating for TG TherapeuticsH.C. Wainwright Stick to Their Buy Rating for TG Therapeutics
investing.com - May 25 at 6:29 PM
TG Therapeutics, Inc. (TGTX) has great growth outlook for 2021TG Therapeutics, Inc. (TGTX) has great growth outlook for 2021
marketingsentinel.com - May 25 at 1:29 PM
TG Therapeutics Announces FDA Acceptance of Biologics License Application for Ublituximab in Combination with UKONIQ® (umbralisib) as a Treatment for Patients with Chronic Lymphocytic Leukemia and Small Lymphocytic LymphomaTG Therapeutics Announces FDA Acceptance of Biologics License Application for Ublituximab in Combination with UKONIQ® (umbralisib) as a Treatment for Patients with Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
finance.yahoo.com - May 25 at 8:29 AM
First Week of July 16th Options Trading For TG Therapeutics (TGTX)First Week of July 16th Options Trading For TG Therapeutics (TGTX)
nasdaq.com - May 23 at 11:52 AM
Is TG Therapeutics, Inc. (NASDAQ:TGTX) a Good Pick for New Investors Now?Is TG Therapeutics, Inc. (NASDAQ:TGTX) a Good Pick for New Investors Now?
stocksregister.com - May 21 at 5:12 PM
Boom Or Bust: Where Does TG Therapeutics, Inc. (NASDAQ:TGTX) Stock Go From Here?Boom Or Bust: Where Does TG Therapeutics, Inc. (NASDAQ:TGTX) Stock Go From Here?
marketingsentinel.com - May 21 at 5:12 PM
TG Therapeutics, Inc. (NASDAQ:TGTX) Surprises Bears With Its OutlookTG Therapeutics, Inc. (NASDAQ:TGTX) Surprises Bears With Its Outlook
marketingsentinel.com - May 18 at 3:00 PM
TG Therapeutics Inc (TGTX) Q1 2021 Earnings Call TranscriptTG Therapeutics Inc (TGTX) Q1 2021 Earnings Call Transcript
finance.yahoo.com - May 10 at 9:30 PM
TG Therapeutics (TGTX) Reports Q1 Loss, Lags Revenue EstimatesTG Therapeutics (TGTX) Reports Q1 Loss, Lags Revenue Estimates
finance.yahoo.com - May 10 at 4:30 PM
TG Therapeutics: Q1 Earnings SnapshotTG Therapeutics: Q1 Earnings Snapshot
mysanantonio.com - May 10 at 7:48 AM
TG Therapeutics Provides Business Update and Reports First Quarter 2021 Financial ResultsTG Therapeutics Provides Business Update and Reports First Quarter 2021 Financial Results
finance.yahoo.com - May 10 at 7:48 AM
TG Therapeutics to Host Conference Call on First Quarter 2021 Financial Results and Business UpdateTG Therapeutics to Host Conference Call on First Quarter 2021 Financial Results and Business Update
finance.yahoo.com - May 6 at 11:57 AM
DateCompanyBrokerageAction
5/18/2021AllakosHC WainwrightInitiated Coverage
2/24/2021AllakosCantor FitzgeraldInitiated Coverage
1/15/2021AllakosBank of AmericaInitiated Coverage
12/21/2020AllakosSVB LeerinkInitiated Coverage
10/22/2020AllakosLifesci CapitalReiterated Rating
3/26/2020AllakosWilliam BlairReiterated Rating
2/27/2020AllakosBarclaysInitiated Coverage
2/4/2020AllakosThe Goldman Sachs GroupReiterated Rating
8/13/2018AllakosJefferies Financial GroupInitiated Coverage
6/17/2021Blueprint MedicinesWedbushLower Price Target
6/17/2021Blueprint MedicinesRobert W. BairdBoost Price Target
4/30/2021Blueprint MedicinesMorgan StanleyLower Price Target
3/30/2021Blueprint MedicinesCredit Suisse GroupInitiated Coverage
12/18/2020Blueprint MedicinesJMP SecuritiesBoost Price Target
12/14/2020Blueprint MedicinesBMO Capital MarketsBoost Price Target
12/2/2020Blueprint MedicinesStifel NicolausInitiated Coverage
10/29/2020Blueprint MedicinesPiper SandlerBoost Price Target
10/16/2020Blueprint MedicinesRaymond JamesBoost Price Target
5/7/2021Ionis PharmaceuticalsUBS GroupUpgrade
3/23/2021Ionis PharmaceuticalsNeedham & Company LLCLower Price Target
3/23/2021Ionis PharmaceuticalsRoyal Bank of CanadaLower Price Target
12/15/2020Ionis PharmaceuticalsCowenUpgrade
10/7/2020Ionis PharmaceuticalsOppenheimerReiterated Rating
9/14/2020Ionis PharmaceuticalsJPMorgan Chase & Co.Initiated Coverage
4/20/2021GalapagosDeutsche Bank AktiengesellschaftInitiated Coverage
2/11/2021GalapagosCitigroupDowngrade
2/10/2021GalapagosMaxim GroupDowngrade
12/17/2020GalapagosSmith Barney CitigroupReiterated Rating
12/17/2020GalapagosBryan, Garnier & CoDowngrade
2/5/2021TG TherapeuticsB. RileyBoost Price Target
6/5/2020TG TherapeuticsEvercore ISIInitiated Coverage
(Data available from 6/23/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.